Sandoz Group AG (OTCMKTS:SDZNY – Get Free Report)’s stock price hit a new 52-week high on Tuesday . The company traded as high as $49.20 and last traded at $49.10, with a volume of 49059 shares. The stock had previously closed at $48.32.
Analyst Ratings Changes
SDZNY has been the topic of several research reports. BNP Paribas lowered shares of Sandoz Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 2nd. UBS Group downgraded Sandoz Group from a “strong-buy” rating to a “hold” rating in a report on Monday, February 3rd.
Check Out Our Latest Stock Report on SDZNY
Sandoz Group Trading Up 1.6 %
About Sandoz Group
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
Recommended Stories
- Five stocks we like better than Sandoz Group
- Why Invest in High-Yield Dividend Stocks?
- Merck: 4 No-Brainer Reasons to Buy This Dip
- Insider Buying Explained: What Investors Need to Know
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- How to Evaluate a Stock Before Buying
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
